Some of the most prominent indicators are Isocitrate Dehydrogenase (IDH) mutations, which are suggestive of a more favorable prognosis in lower-grade gliomas, and MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation, which is a predictive factor for enhanced responses to specific chemotherapeutic interventions [12,13]. Here, IDH2 is linked to central nervous system cancer.